ADVANCED MOLECULAR AND EXPERIMENTAL HEMATOLOGY
Academic Year 2022/2023 - Teacher: CESARINA GIALLONGOExpected Learning Outcomes
Acquisition of the basic knowledge necessary for the choice and use of omics for the diagnosis and attribution of the risk of progression of the main neoplastic hemopathies.
At the end of the course, students will be able to choose and develop the most suitable technological approach for understanding the pathophysiological basis of hematological neoplasms, with particular reference to multiple myeloma, non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Course Structure
Required Prerequisites
Detailed Course Content
After a general overview of the main omics technologies developed for understanding the main hematological neoplasms, the student will be introduced to the application of gene therapy, immunotherapy and metabolomics used for the development of precision medicine. At each lesson, the discussion of a scientific article will make it possible to critically highlight the experimental approach adopted for understanding the pathology of interest.
Textbook Information
Manuale di malattie del
Sangue, Elsevier di
Bosi, De Stefano, Di Raimondo, La Nasa
Hematology.
Pathophysiology, diagnosis and treatment, Esculapio di
Pier Luigi Zinzani, Sante Tura, Michele Cavo
Ematologia Smart, Idelson Gnocchi di Fiorina Giona
Gene and Cell Therapy: Biology and Applications, Springer Link di Giridhara R. Jayandharan
Chimeric Antigen Receptor T-Cell Therapies for Cancer 1st Edition A Practical Guide, Elsevier di Daniel Lee Nirali N. ShahCourse Planning
Subjects | Text References | |
---|---|---|
1 | The epigenetic basis of hematopoietic stem cell aging | |
2 | Telomerase gene therapy | |
3 | Modeling human bone marrow failure syndromes using pluripotent stem cells and genome engineering | |
4 | Epigenetic manipulation of immune response | |
5 | Systemic metabolomic profiling of acute myeloid leukemia | |
6 | Thalassemias and sickle cell disease | |
7 | Bispecific antibodies engineering for immunotherapy in hematological malignancies | |
8 | Engineering natural killer cells for cancer immunotherapy | |
9 | Mechanisms of resistance to cellular therapy by using CAR-T and CAR-NK in multiple myeloma | |
10 | Preclinical models for the development of cellular therapies in multiple myeloma | |
11 | Minimal residual disease assesment in multiple myeloma: next generation flow cytometry, mass spectometry, liquid biopsy, dielectrophoresis | |
12 | Systems thinkings |